Navigation Links
AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
Date:12/5/2011

financial position offer great business opportunities. I am excited about the opportunity to contribute to the further success of AFFiRiS at this particular stage of the company's development."

"Our growing development-pipeline creates more and more business opportunities," comments Walter Schmidt, co-founder and CEO of AFFiRiS, "Together with Ali we will exploit these opportunities further and add to our successful track record of business alliances. The experience he has gained in senior positions at two top ten pharmaceutical companies is a valuable addition to AFFiRiS's in-house expertise."

About AFFiRiS AG (date December 2011):

On the basis of the company's own patent positions AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, Hypertension and several other conditions with unmet medical need and attractive market sizes. Alzheimer's is the current lead indication. For the Alzheimer's vaccine program, a license and option agreement with GlaxoSmithKline was closed in October 2008, triggering an upfront payment of EUR 22.5 million. The contract envisages (milestone-dependent) payments of up to EUR 430 million. A first milestone payment of EUR 10 million was made in October 2009 followed by EUR 3.5 million as announced recently. AFFiRiS currently employs 82 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

Contact AFFiRiS AG:
Julia Bock
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43/(0)1/798-15-75-303
E  julia.bock@affiris.com  
W http://www.affiris.com


Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43/(0)1/505-70-44
E contact@
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
8. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
9. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
10. Burrill & Company Invests in Taiwan Liposome Company
11. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... in the media. A new study by Dr. Yaniv ... journal of Israel,s National Security College, describes how our ... , "Information warfare" plays a crucial role ... than conventional weapons. Therefore, the information warfare against terrorist ...
... 17 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ... April 14, 2009, from the Listing Qualifications Department of ... does not comply with the $10.0 million minimum stockholders, ... Market set forth in NASDAQ Marketplace Rule 5450(b)(1)(A). NASDAQ,s ...
... China, April 17 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, ... or the "Company"),one of the leading plasma-based ... ("PRC"), announced that it has completed the ... 90% equity interest in,Chongqing Dalin Biologic Technologies ...
Cached Biology Technology:Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2Sunesis Pharmaceuticals Receives NASDAQ Notification 2Sunesis Pharmaceuticals Receives NASDAQ Notification 3China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... new details about how estrogen can activate natural pathways that ... the possibility that estrogen therapy may overcome resistance to certain ... 7 issue of the Journal of the National ... such as chemotherapy or hormonal therapy fail to cause tumor ...
... spot cracks in space shuttle foam, see biological agents ... radiation, was the focus of a recent symposium at ... The session was organized and chaired by experts ... at Yale, and Xi-Cheng Zhang, professor and director of ...
... implants allow the deaf to hear. Their brains learn ... provide to the cochlea as sound. , A Stanford ... Maryland to see if children with cochlear implants were ... their ability to read lips. In other words, did ...
Cached Biology News: Researchers uncover mechanisms of estrogen in promoting cell death in breast cancer 2T-rays: New imaging technology spotlighted by American Chemical Society 2Sooner is better with cochlear implants, Stanford scientist shows 2Sooner is better with cochlear implants, Stanford scientist shows 3
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
Sheep Serum US Origin...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: